Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2014-2017

ABSTRACT

The purpose of this study is to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Detailed Description Viral infections are common complications after allo-HSCT. With wide use of HLA-mismatch, unrelated and cord blood donors as alternative sources of hematopoietic stem cells, and anti-thymocyte globulin (ATG) as the standard prophylaxis of graft versus host disease (GVHD) in HLA-mismatch and unrelated donor transplantation, allo-HSCT recipients are at increasing risk for viral infections. Till now, CMV remains one of the most important viruses and causes of death in the recipients of allo-HSCT. Approximately 75% of CMV-seropositive recipients develop CMV reactivation, and 20-30% of these patients develop CMV disease without intervention. Ganciclovir is the first-line treatment of CMV diseases. However, bone marrow suppression, which is the main and common side effect, limits the utility of ganciclovir in allo-HSCT recipients. Besides, ganciclovir and other antiviral agents resistance has been reported up to 28%. Since it has been known that specific immune response to CMV is important to control reactivation, CMV-specific CTL has been used in prophylaxis and treatment of CMV viremia in several studies. However, the production of CTL requires time. Mesenchymal stem cells (MSC) are a form of multipotent adult stem cells that can be isolated from bone marrow (BM), adipose tissue, and cord blood. In vivo experiment showed that MSCs have antimicrobial activity. In this trial, we will use MSCs in the recipients with refractory CMV infections. More... »

URL

https://clinicaltrials.gov/show/NCT02083731

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).\n\nDetailed Description\nViral infections are common complications after allo-HSCT. With wide use of HLA-mismatch, unrelated and cord blood donors as alternative sources of hematopoietic stem cells, and anti-thymocyte globulin (ATG) as the standard prophylaxis of graft versus host disease (GVHD) in HLA-mismatch and unrelated donor transplantation, allo-HSCT recipients are at increasing risk for viral infections. Till now, CMV remains one of the most important viruses and causes of death in the recipients of allo-HSCT. Approximately 75% of CMV-seropositive recipients develop CMV reactivation, and 20-30% of these patients develop CMV disease without intervention. Ganciclovir is the first-line treatment of CMV diseases. However, bone marrow suppression, which is the main and common side effect, limits the utility of ganciclovir in allo-HSCT recipients. Besides, ganciclovir and other antiviral agents resistance has been reported up to 28%. Since it has been known that specific immune response to CMV is important to control reactivation, CMV-specific CTL has been used in prophylaxis and treatment of CMV viremia in several studies. However, the production of CTL requires time. Mesenchymal stem cells (MSC) are a form of multipotent adult stem cells that can be isolated from bone marrow (BM), adipose tissue, and cord blood. In vivo experiment showed that MSCs have antimicrobial activity. In this trial, we will use MSCs in the recipients with refractory CMV infections.", 
    "endDate": "2017-01-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02083731", 
    "keywords": [
      "stem cell", 
      "CMV infection", 
      "hematopoietic stem cell transplant", 
      "efficacy", 
      "Mesenchymal Stromal Cell", 
      "stem cell treatment", 
      "CMV", 
      "infection", 
      "allogeneic hematopoietic stem cell transplantation", 
      "viral infection", 
      "common complication", 
      "wide use", 
      "mismatch", 
      "blood donor", 
      "alternative source", 
      "hematopoietic stem cell", 
      "Antilymphocyte Serum", 
      "prophylaxis", 
      "graft host disease", 
      "Graft vs Host Disease", 
      "unrelated donor", 
      "recipient", 
      "risk", 
      "important virus", 
      "death", 
      "CMV reactivation", 
      "patient", 
      "CMV disease", 
      "intervention", 
      "ganciclovir", 
      "first-line treatment", 
      "bone marrow suppression", 
      "common side effect", 
      "utility", 
      "antiviral agent", 
      "specific immune response", 
      "reactivation", 
      "specific CTL", 
      "viremia", 
      "CTL", 
      "adult stem cell", 
      "bone marrow", 
      "adipose tissue", 
      "Fetal Blood", 
      "vivo experiment", 
      "antimicrobial activity", 
      "trial"
    ], 
    "name": "Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02083731"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00016.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.411634.5", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410740.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.12981.33", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413435.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413352.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413087.9", 
        "type": "Organization"
      }
    ], 
    "startDate": "2014-01-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/leu.2010.310", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027386114", 
          "https://doi.org/10.1038/leu.2010.310"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2008.162", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044285303", 
          "https://doi.org/10.1038/bmt.2008.162"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02083731"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02083731'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02083731'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02083731'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02083731'


 

This table displays all metadata directly associated to this object as RDF triples.

87 TRIPLES      16 PREDICATES      70 URIs      56 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02083731 schema:about anzsrc-for:3048
2 anzsrc-for:3103
3 schema:description The purpose of this study is to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Detailed Description Viral infections are common complications after allo-HSCT. With wide use of HLA-mismatch, unrelated and cord blood donors as alternative sources of hematopoietic stem cells, and anti-thymocyte globulin (ATG) as the standard prophylaxis of graft versus host disease (GVHD) in HLA-mismatch and unrelated donor transplantation, allo-HSCT recipients are at increasing risk for viral infections. Till now, CMV remains one of the most important viruses and causes of death in the recipients of allo-HSCT. Approximately 75% of CMV-seropositive recipients develop CMV reactivation, and 20-30% of these patients develop CMV disease without intervention. Ganciclovir is the first-line treatment of CMV diseases. However, bone marrow suppression, which is the main and common side effect, limits the utility of ganciclovir in allo-HSCT recipients. Besides, ganciclovir and other antiviral agents resistance has been reported up to 28%. Since it has been known that specific immune response to CMV is important to control reactivation, CMV-specific CTL has been used in prophylaxis and treatment of CMV viremia in several studies. However, the production of CTL requires time. Mesenchymal stem cells (MSC) are a form of multipotent adult stem cells that can be isolated from bone marrow (BM), adipose tissue, and cord blood. In vivo experiment showed that MSCs have antimicrobial activity. In this trial, we will use MSCs in the recipients with refractory CMV infections.
4 schema:endDate 2017-01-01T00:00:00Z
5 schema:keywords Antilymphocyte Serum
6 CMV
7 CMV disease
8 CMV infection
9 CMV reactivation
10 CTL
11 Fetal Blood
12 Graft vs Host Disease
13 Mesenchymal Stromal Cell
14 adipose tissue
15 adult stem cell
16 allogeneic hematopoietic stem cell transplantation
17 alternative source
18 antimicrobial activity
19 antiviral agent
20 blood donor
21 bone marrow
22 bone marrow suppression
23 common complication
24 common side effect
25 death
26 efficacy
27 first-line treatment
28 ganciclovir
29 graft host disease
30 hematopoietic stem cell
31 hematopoietic stem cell transplant
32 important virus
33 infection
34 intervention
35 mismatch
36 patient
37 prophylaxis
38 reactivation
39 recipient
40 risk
41 specific CTL
42 specific immune response
43 stem cell
44 stem cell treatment
45 trial
46 unrelated donor
47 utility
48 viral infection
49 viremia
50 vivo experiment
51 wide use
52 schema:name Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant
53 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02083731
54 schema:sdDatePublished 2019-03-07T15:25
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N8c36a834554b4a0ca6410f109097cbcc
57 schema:sponsor https://www.grid.ac/institutes/grid.12981.33
58 https://www.grid.ac/institutes/grid.410740.6
59 https://www.grid.ac/institutes/grid.411634.5
60 https://www.grid.ac/institutes/grid.413087.9
61 https://www.grid.ac/institutes/grid.413352.2
62 https://www.grid.ac/institutes/grid.413435.4
63 schema:startDate 2014-01-01T00:00:00Z
64 schema:subjectOf sg:pub.10.1038/bmt.2008.162
65 sg:pub.10.1038/leu.2010.310
66 schema:url https://clinicaltrials.gov/show/NCT02083731
67 sgo:license sg:explorer/license/
68 sgo:sdDataset clinical_trials
69 rdf:type schema:MedicalStudy
70 N8c36a834554b4a0ca6410f109097cbcc schema:name Springer Nature - SN SciGraph project
71 rdf:type schema:Organization
72 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
73 rdf:type schema:DefinedTerm
74 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
75 rdf:type schema:DefinedTerm
76 sg:pub.10.1038/bmt.2008.162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044285303
77 https://doi.org/10.1038/bmt.2008.162
78 rdf:type schema:CreativeWork
79 sg:pub.10.1038/leu.2010.310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027386114
80 https://doi.org/10.1038/leu.2010.310
81 rdf:type schema:CreativeWork
82 https://www.grid.ac/institutes/grid.12981.33 schema:Organization
83 https://www.grid.ac/institutes/grid.410740.6 schema:Organization
84 https://www.grid.ac/institutes/grid.411634.5 schema:Organization
85 https://www.grid.ac/institutes/grid.413087.9 schema:Organization
86 https://www.grid.ac/institutes/grid.413352.2 schema:Organization
87 https://www.grid.ac/institutes/grid.413435.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...